
Roche has discontinued dosing in a Phase III trial of its tominersen treatment for Huntington’s disease, following discouraging initial data.

Israeli pharma firm Teva is joining forces with technology giant Intel to tackle the debilitating disease Huntington’s with cutting-edge wearable …

Roche is to pay California-based Isis Pharmaceuticals $30 million upfront to cement a new alliance in which the firms will …
Leading pharma companies have come together for a major new research collaboration aimed at improving clinical trials for Alzheimer’s, Parkinson’s, …

